Objectives: The study measures trends in the profile of patients with chronic hepatitis B virus linked to care in Italy. Methods: A cross-sectional, multicenter, observational cohort (PITER cohort) of consecutive patients with hepatitis B surface antigen (HBsAg) over the period 2019-2021 from 46 centers was evaluated. The reference was the MASTER cohort collected over the years 2012-2015. Standard statistical methods were used. Results: The PITER cohort enrolled 4583 patients, of whom 21.8% were non-Italian natives. Compared with those in MASTER, the patients were older and more often female. The prevalence of hepatitis B e antigen (HBeAg) declined (7.2% vs 12.3; P <0.0001) and that of anti-hepatitis D virus (HDV) remained stable (9.3% vs 8.3%). In both cohorts, about 25% of the patients had cirrhosis, and those in the PITER cohort were older. HBeAg-positive was 5.0% vs 12.6% (P <0.0001) and anti-HDV positive 24.8% vs 17.5% (P <0.0017). In the logistic model, the variables associated with cirrhosis were anti-HDV-positive (odds ratio = 10.08; confidence interval 7.63-13.43), age, sex, and body mass index; the likelihood of cirrhosis was reduced by 40% in the PITER cohort. Among non-Italians, 12.3% were HBeAg-positive (vs 23.4% in the MASTER cohort; P <0.0001), and 12.3% were anti-HDV-positive (vs 11.1%). Overall, the adherence to the European Association for the Study of the Liver recommendations for antiviral treatment increased over time. Conclusion: Chronic hepatitis B virus infection appears to be in the process of becoming under control in Italy; however, HDV infection is still a health concern in patients with cirrhosis and in migrants.

Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination / Brancaccio, G.; Coco, B.; Nardi, A.; Quaranta, M. G.; Tosti, M. E.; Ferrigno, L.; Cacciola, I.; Messina, V.; Chessa, L.; Morisco, F.; Milella, M.; Barbaro, F.; Ciancio, A.; Russo, F. P.; Coppola, N.; Blanc, P.; Claar, E.; Verucchi, G.; Puoti, M.; Zignego, A. L.; Chemello, L.; Madonia, S.; Fagiuoli, S.; Marzano, A.; Ferrari, C.; Lampertico, P.; Di Marco, V.; Craxi, A.; Santantonio, T. A.; Raimondo, G.; Brunetto, M. R.; Gaeta, G. B.; Kondili, L. A.; Pasulo, L.; Coppola, C.; Pisano, F.; Romano, M.; Porcu, C.; Bottalico, I. F.; Cossiga, V.; Tata, X.; Sagnelli, C.; Pierotti, P.; Degasperi, E.; Rosato, V.; Badia, L.; Ieluzzi, D.; Monti, M.; Bavetta, M. G.; Cavalletto, L.; Toniutto, P.; Fornasiere, E.; Colecchia, A.; Ferrarese, A.; Nardone, G.; Rocco, A.; Vigano, M.; Foschi, F. G.; Conti, F.; Morsica, G.; Salpietro, S.; Torti, C.; Costa, C.; Federico, A.; Dallio, M.; Giorgini, A.; Anselmo, M.; De Leo, P.; Zaltron, S.; Cambianica, A.; Piscaglia, F.; Serio, I.; Schivazappa, S.; Mastroianni, A.; Chidichimo, L.; Massari, M.; Mazzaro, C.; Marrone, A.; D'Amore, F. M.; D'Offizi, G.; Licata, A.; Niro, G. A.; Pollicino, T.; Aghemo, A.. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 129:(2023), pp. 266-273. [10.1016/j.ijid.2023.02.006]

Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

Messina V.;Morisco F.;Milella M.;Barbaro F.;Russo F. P.;Puoti M.;Di Marco V.;Cossiga V.;Rosato V.;Badia L.;Colecchia A.;Nardone G.;Rocco A.;Dallio M.;Anselmo M.;De Leo P.;Massari M.;
2023

Abstract

Objectives: The study measures trends in the profile of patients with chronic hepatitis B virus linked to care in Italy. Methods: A cross-sectional, multicenter, observational cohort (PITER cohort) of consecutive patients with hepatitis B surface antigen (HBsAg) over the period 2019-2021 from 46 centers was evaluated. The reference was the MASTER cohort collected over the years 2012-2015. Standard statistical methods were used. Results: The PITER cohort enrolled 4583 patients, of whom 21.8% were non-Italian natives. Compared with those in MASTER, the patients were older and more often female. The prevalence of hepatitis B e antigen (HBeAg) declined (7.2% vs 12.3; P <0.0001) and that of anti-hepatitis D virus (HDV) remained stable (9.3% vs 8.3%). In both cohorts, about 25% of the patients had cirrhosis, and those in the PITER cohort were older. HBeAg-positive was 5.0% vs 12.6% (P <0.0001) and anti-HDV positive 24.8% vs 17.5% (P <0.0017). In the logistic model, the variables associated with cirrhosis were anti-HDV-positive (odds ratio = 10.08; confidence interval 7.63-13.43), age, sex, and body mass index; the likelihood of cirrhosis was reduced by 40% in the PITER cohort. Among non-Italians, 12.3% were HBeAg-positive (vs 23.4% in the MASTER cohort; P <0.0001), and 12.3% were anti-HDV-positive (vs 11.1%). Overall, the adherence to the European Association for the Study of the Liver recommendations for antiviral treatment increased over time. Conclusion: Chronic hepatitis B virus infection appears to be in the process of becoming under control in Italy; however, HDV infection is still a health concern in patients with cirrhosis and in migrants.
2023
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination / Brancaccio, G.; Coco, B.; Nardi, A.; Quaranta, M. G.; Tosti, M. E.; Ferrigno, L.; Cacciola, I.; Messina, V.; Chessa, L.; Morisco, F.; Milella, M.; Barbaro, F.; Ciancio, A.; Russo, F. P.; Coppola, N.; Blanc, P.; Claar, E.; Verucchi, G.; Puoti, M.; Zignego, A. L.; Chemello, L.; Madonia, S.; Fagiuoli, S.; Marzano, A.; Ferrari, C.; Lampertico, P.; Di Marco, V.; Craxi, A.; Santantonio, T. A.; Raimondo, G.; Brunetto, M. R.; Gaeta, G. B.; Kondili, L. A.; Pasulo, L.; Coppola, C.; Pisano, F.; Romano, M.; Porcu, C.; Bottalico, I. F.; Cossiga, V.; Tata, X.; Sagnelli, C.; Pierotti, P.; Degasperi, E.; Rosato, V.; Badia, L.; Ieluzzi, D.; Monti, M.; Bavetta, M. G.; Cavalletto, L.; Toniutto, P.; Fornasiere, E.; Colecchia, A.; Ferrarese, A.; Nardone, G.; Rocco, A.; Vigano, M.; Foschi, F. G.; Conti, F.; Morsica, G.; Salpietro, S.; Torti, C.; Costa, C.; Federico, A.; Dallio, M.; Giorgini, A.; Anselmo, M.; De Leo, P.; Zaltron, S.; Cambianica, A.; Piscaglia, F.; Serio, I.; Schivazappa, S.; Mastroianni, A.; Chidichimo, L.; Massari, M.; Mazzaro, C.; Marrone, A.; D'Amore, F. M.; D'Offizi, G.; Licata, A.; Niro, G. A.; Pollicino, T.; Aghemo, A.. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 129:(2023), pp. 266-273. [10.1016/j.ijid.2023.02.006]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/981547
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact